18889881171
Kalkine 0
countryflagUS

Belite Bio Inc ADR

Healthcare US BLTE

64.38USD
0.80(1.26%)

Last update at 2025-07-15T16:51:00Z

Day Range

64.1265.30
LowHigh

52 Week Range

31.0086.53
LowHigh

Fundamentals

  • Previous Close 63.58
  • Market Cap2028.77M
  • Volume145850
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-35.29875M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.1

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -12.64800M -9.66600M -5.75200M
Minority interest - - -
Net income -12.47500M -9.79200M -5.75300M
Selling general administrative 3.95M 2.38M 2.06M
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation 0.20M 0.03M 0.02M
Ebit -12.82100M -9.79700M -5.74300M
Ebitda -12.43400M -9.63600M -5.71400M
Depreciation and amortization 0.39M 0.16M 0.03M
Non operating income net other - - -
Operating income -12.82100M -9.79700M -5.74300M
Other operating expenses 12.82M 9.80M 5.74M
Interest expense 0.02M 0.00500M 0.02M
Tax provision 0.00000M 0.00000M 0.00100M
Interest income 0.02M 0.00500M 0.01M
Net interest income 0.00700M 0.00500M -0.00900M
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense -0.17300M 0.13M 0.00100M
Total revenue 0.00000M 0.00000M 0.00000M
Total operating expenses 12.82M 9.80M 5.74M
Cost of revenue - - -
Total other income expense net 0.17M 0.13M -0.00900M
Discontinued operations - - -
Net income from continuing ops -12.64800M -9.66600M -5.75300M
Net income applicable to common shares - -9.66600M -5.75300M
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 94.64M 44.27M 18.35M 25.74M
Intangible assets 3.23M - - -
Earning assets - - - -
Other current assets 0.92M 0.72M 0.06M 0.01000M
Total liab 4.21M 2.77M 33.44M 32.78M
Total stockholder equity 90.43M 41.50M -15.09300M -7.03700M
Deferred long term liab - - 0.81M -
Other current liab 3.33M 1.91M 1.64M 0.97M
Common stock 0.00300M 0.00300M 0.00100M 0.00100M
Capital stock 0.00300M 0.00300M 0.00100M 0.00100M
Retained earnings -71.50300M -39.87100M -27.22300M -17.55700M
Other liab - - - -
Good will - - - -
Other assets 0.00000M - 0.82M 0.03M
Cash 88.16M 42.09M 17.34M 25.62M
Cash and equivalents - - - -
Total current liabilities 3.63M 2.10M 1.64M 0.97M
Current deferred revenue - - - -
Net debt -87.27100M -41.22300M -17.34400M -25.61800M
Short term debt 0.31M 0.20M - -
Short long term debt - - - -
Short long term debt total 0.89M 0.87M - -
Other stockholder equity 162.31M 81.76M 12.32M 10.56M
Property plant equipment - - 0.09M 0.05M
Total current assets 89.94M 42.81M 17.43M 25.67M
Long term investments - - - -
Net tangible assets - - -15.09300M -7.03700M
Short term investments - - - -
Net receivables 0.87M 0.02M 0.02M 0.04M
Long term debt - - - -
Inventory - -0.01900M - -
Accounts payable - - - -
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -0.37400M -0.39200M -0.19600M -0.04400M
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.17M 0.09M 0.82M 0.00700M
Deferred long term asset charges - - - -
Non current assets total 4.70M 1.47M 0.92M 0.07M
Capital lease obligations 0.89M 0.87M - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -0.39400M -0.05600M -0.02000M
Change to liabilities - 0.04M -0.01900M
Total cashflows from investing activities - -0.05600M -0.02000M
Net borrowings - - -2.31900M
Total cash from financing activities 36.96M -0.58300M 28.06M
Change to operating activities - 0.59M -0.05400M
Net income -12.64800M -9.66600M -5.75300M
Change in cash 24.75M -8.27400M 23.60M
Begin period cash flow 17.34M 25.62M 2.02M
End period cash flow 42.09M 17.34M 25.62M
Total cash from operating activities -11.45800M -7.47400M -4.44200M
Issuance of capital stock 0.00000M 0.00000M 30.29M
Depreciation 0.20M 0.03M 0.02M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - 0.00400M
Sale purchase of stock - - -
Other cashflows from financing activities 36.96M -0.58300M 30.01M
Change to netincome - 1.52M 1.36M
Capital expenditures 0.39M 0.07M 0.02M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital -0.49100M 0.64M -0.06900M
Stock based compensation 1.48M 1.53M 1.36M
Other non cash items - -0.00800M -
Free cash flow -11.85200M -7.54800M -4.46200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BLTE
Belite Bio Inc ADR		 0.80 1.26% 64.38 - - - 20.47 -35.6078
NVO
Novo Nordisk A/S		 -1.45 2.10% 67.49 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 67.01 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.85 1.66% 464.50 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -18.155 3.18% 552.43 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Belite Bio Inc ADR

12750 High Bluff Drive, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of Directors & CEO 1978
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. CFO & Director 1984
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer 1966
Ms. Ching-Chen Chiu M.Sc. VP of Clinical Operations 1970
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors & CEO 1979
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. CFO & Director 1985
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer 1967
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.